Company: STAA
Filing Date: 2025-08-29
Form Type: PREM14A
Source: 0001193125-25-192889
Chunk: 96

Company: STAAR SURGICAL CO
Filing Date: 2025-08-29
Form: PREM14A
Chunk 96
---
 other reasons, the inherent
difficulty of predicting financial performance for future periods and the uncertainty, unpredictability and subjectivity of underlying assumptions and estimates. In connection with the Merger, prior to the execution of the Merger Agreement,
management prepared and provided certain nonpublic financial projections regarding STAAR’s future operations to the Board, Citi and Alcon, in each case as described below.

Upon discussion with and at the direction of the Board, STAAR’s management prepared certain unaudited prospective financial information
for STAAR on a standalone basis for fiscal years 2025 through 2030, as reflected below (the “Projections”), which assumed an annual net sales growth rate of approximately 10% beginning in 2027.

In advance of the Projections being finalized and approved by the Board, STAAR management prepared certain preliminary unaudited prospective
financial information for STAAR on a standalone basis for fiscal years 2025 through 2027, as summarized below (the “July Diligence Projections” and together with the Projections, the

-58-

“financial projections”). The July Diligence Projections were provided to Alcon in July 2025 as part of its due diligence process. Following the preparation of the July Diligence
Projections, STAAR’s management team continued to refine and assess its estimates and judgments for STAAR’s future operations, incorporating further risk-adjusted expectations for net sales of ICLs and new product introductions.
Management considered multiple factors, including emerging competition in China, that could impact growth rates and overall future financial results to arrive at the expectations reflected in the Projections. Relative to the Projections, the July
Diligence Projections assumed incremental ICL net sales in 2026 and 2027 and incremental net sales attributable to ongoing and accelerated new product introductions in 2027. In early August 2025, the Projections were provided to the Board in
connection with its evaluation of the Merger, and were provided to Citi and approved by STAAR for Citi’s use and reliance in connection with Citi’s financial analysis and opinion as summarized in “Proposal 1: Adoption of the Merger Agreement—Opinion of STAAR’s Financial Advisor.”

Both of the Projections and the July Diligence Projections
reflect STAAR on a standalone basis without giving effect to the Merger, including any impact of the negotiation or execution of the Merger Agreement, the expenses that may be incurred in connection with the Merger,